BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9193322)

  • 1. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.
    Stiff PJ; Bayer R; Kerger C; Potkul RK; Malhotra D; Peace DJ; Smith D; Fisher SG
    J Clin Oncol; 1997 Apr; 15(4):1309-17. PubMed ID: 9193322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
    Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS;
    Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report.
    Stiff PJ; Veum-Stone J; Lazarus HM; Ayash L; Edwards JR; Keating A; Klein JP; Oblon DJ; Shea TC; Thomé S; Horowitz MM
    Ann Intern Med; 2000 Oct; 133(7):504-15. PubMed ID: 11015163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.
    Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD
    Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
    Ayash LJ; Wheeler C; Fairclough D; Schwartz G; Reich E; Warren D; Schnipper L; Antman K; Frei E; Elias A
    J Clin Oncol; 1995 Aug; 13(8):2043-9. PubMed ID: 7636547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
    Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
    Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.
    Legros M; Dauplat J; Fleury J; Cure H; Suzanne F; Chassagne J; Bay JO; Sol C; Canis M; Condat P; Choufi B; Tavernier F; Glenat C; Chollet P; Plagne R
    J Clin Oncol; 1997 Apr; 15(4):1302-8. PubMed ID: 9193321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.